LOCAL HOSPITAL HEADER

GP NAME

PRACTICE NAME

PRACTICE ADDRESS

DATE

Dear Dr GP NAME,

Re: MifeMiso - A randomised placebo-controlled trial of mifepristone and misoprostol versus misoprostol alone in the medical management of missed miscarriage

Name	
DOB	
Address	

Your patient has kindly agreed to take part in the MifeMiso Study - a multi-centre, randomised-controlled, blinded study of mifepristone plus misoprostol versus placebo plus misoprostol for the medical management of missed miscarriage. This study is funded by a Health Technology Assessment award from the National Institute for Health Research and granted regulatory approval by West Midlands - Edgbaston Research Ethics Committee.

Your patient has been randomised to either the Intervention Group, taking a single oral dose of 200mg mifepristone, or the Non-Intervention Group, taking placebo. Both groups will subsequently receive 800mcg misoprostol two days later. Since this is a double blind study, neither the participant nor our study investigators will know the treatment allocation of your patient. Your patient has the contact details of our research team members in case of any difficulties.

We do not anticipate that the participation of your patient in our study will affect your care for her, and we will not ask you to carry out any study-related investigations or interventions.

This letter is for information only.

If you would like any further details, please feel free to contact our Trial Co-ordinator via mifemiso@trials.bham.ac.uk or 0121 414 9011.

Thank you for your support.

Yours sincerely,

LOCAL PRINCIPAL INVESTIGATOR